Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemoporphyrin Photodynamic Therapy for Recurrent Respiratory Papillomatosis
ChiCTR2400086211Phase 2Recruiting
- Sponsor
- BenQ Medical Center
- Start
- Jul 2024
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hemoporfin in Laryngeal papilloma (RRP), sponsored by BenQ Medical Center. Primary endpoints: Recurrence-free survival and Safety of photodynamic therapy. Started Jul 2024; status: recruiting.
02
Drugs
hemoporfin
03
Conditions
Laryngeal papilloma (RRP)
Beyond the preview
Go deeper on ChiCTR2400086211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086211.